Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181314 | 0.98 | DHODH (0.34) | DHODHTRPM4PTGDRITGB1ITGA4 | |
| Lithium SCHEMBL7182005 | 0.94 | DHODH (0.35) | DHODHPTGDRHDAC1HDAC2HDAC8 | |
| Lithium SCHEMBL7189334 | 0.92 | ACACB (0.34) | DHODHHDAC1HDAC2HDAC8ACACB | |
| SCHEMBL7181996 | 0.92 | DHODH (0.35) | DHODHPTGDRHDAC1HDAC2HDAC8 | |
| SCHEMBL7189324 | 0.90 | ACACB (0.34) | DHODHHDAC1HDAC2HDAC8ACACB | |
| Lithium SCHEMBL7183495 | 0.89 | HDAC1 (0.36) | ITGB1ITGA4HDAC1HDAC2HDAC8 | |
| SCHEMBL7187626 | 0.89 | SMN1; SMN2 (0.34) | TRPM4ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7183488 | 0.87 | HDAC1 (0.36) | ITGB1ITGA4HDAC1HDAC2HDAC8 | |
| Lithium SCHEMBL7189444 | 0.87 | TYK2 (0.36) | TRPM4ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7183722 | 0.86 | DHODH (0.35) | DHODHTRPM4PTGDRITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | DHODH 2946/4885TRPM4 3654/4885PTGDR 3402/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | DHODH 2970/4885TRPM4 3840/4885PTGDR 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.